0001209191-23-002178.txt : 20230105
0001209191-23-002178.hdr.sgml : 20230105
20230105210640
ACCESSION NUMBER: 0001209191-23-002178
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230103
FILED AS OF DATE: 20230105
DATE AS OF CHANGE: 20230105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lee Kevin
CENTRAL INDEX KEY: 0001776938
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 23513499
MAIL ADDRESS:
STREET 1: C/O BICYCLE THERAPEUTICS LIMITED
STREET 2: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB223AT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: BLOCKS A & B, PORTWAY BUILDING
STREET 2: GRANTA PARK, GREAT ABINGTON
CITY: CAMBRIDGE
STATE: X0
ZIP: CB21 6GS
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: BLOCKS A & B, PORTWAY BUILDING
STREET 2: GRANTA PARK, GREAT ABINGTON
CITY: CAMBRIDGE
STATE: X0
ZIP: CB21 6GS
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
DATE OF NAME CHANGE: 20181212
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-03
0
0001761612
BICYCLE THERAPEUTICS plc
BCYC
0001776938
Lee Kevin
C/O BICYCLE THERAPEUTICS PLC
BLOCKS A & B, PORTWAY BUILDING
CAMBRIDGE
X0
CB21 6GS
UNITED KINGDOM
1
1
0
0
Chief Executive Officer
Ordinary Shares
2023-01-03
4
A
0
57500
0.00
A
332585
D
Ordinary Shares
2023-01-03
4
S
0
6000
29.06
D
326585
D
Employee Stock Option (right to buy)
29.60
2023-01-03
4
A
0
115000
0.00
A
2033-01-03
Ordinary Shares
115000
115000
D
Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2024 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
Each RSU represents a contingent right to receive one ordinary share.
Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.545 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares in 36 equal monthly installments thereafter.
/s/ Lee Kalowski, Attorney-in-Fact
2023-01-05